Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belimumab and alopecia areata: No clear safety signal in a multicentre case series and pharmacovigilance analysis.

Annales de dermatologie et de venereologie·2026
Same author

Diffuse alveolar hemorrhage in antiphospholipid syndrome: Clinical presentation and prognosis.

Respiratory medicine·2026
Same author

French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children.

La Revue de medecine interne·2023
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

When local phytotherapies meet biomedicine. Cross-sectional study of knowledge and intercultural practices against malaria in Eastern French Guiana.

Journal of ethnopharmacology·2021
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis

Published on: July 12, 2011

[Antiphospholipid antibodies in practice].

M Miyara1, M-C Diemert, Z Amoura

  • 1Laboratoire d'immunochimie, centre de référence maladies auto-immunes et systémiques rares lupus et syndrome des anticorps antiphospholipides, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France. makoto.miyara@psl.aphp.fr

La Revue De Medecine Interne
|November 22, 2011
PubMed
Summary
This summary is machine-generated.

Antiphospholipid syndrome (APS) diagnosis relies on specific antibodies, but assay standardization remains a challenge. Consistent laboratory analysis of sequential samples is crucial for accurate patient monitoring.

More Related Videos

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Related Experiment Videos

Last Updated: May 27, 2026

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis

Published on: July 12, 2011

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Area of Science:

  • Immunology
  • Rheumatology
  • Clinical Chemistry

Context:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder linked to thrombosis and obstetrical complications.
  • Diagnosis requires detecting specific antiphospholipid antibodies (aPLs) like lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein1.
  • Emerging autoantibodies show potential for APS diagnosis when standard tests are negative.

Purpose:

  • To summarize the diagnostic criteria and current challenges in antiphospholipid syndrome (APS) detection.
  • To highlight the need for improved standardization in antiphospholipid antibody testing.
  • To emphasize the importance of consistent laboratory analysis for APS patient monitoring.

Summary:

  • APS diagnosis involves identifying specific autoantibodies, with ongoing research into novel markers.
  • Current antiphospholipid antibody assays lack standardization, leading to significant inter-laboratory variability.
  • Consistent analysis of consecutive patient samples within the same laboratory is essential for reliable APS monitoring.

Impact:

  • Standardization of antiphospholipid antibody assays would improve diagnostic accuracy and reduce variability.
  • Enhanced diagnostic tools could lead to earlier and more effective management of APS.
  • Optimized biological monitoring will improve patient outcomes and reduce thrombotic and obstetrical events.